Zeposia (Bristol Myers Squibb) treats relapsing MS– $1.6 billion.
Tepezza (Horizon Therapeutics) deals with thyroid eye illness– $1.4 billion.
© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
Palforzia (Aimmune) deals with peanut allergies– $1.5 billion.
Nexletol (Esperion/Daiichi Sankyo) deals with cholesterol and heart disease– $1.8 billion.
The five greatest drug approvals in the very first half of 2020 and their predicted 2026 sales:.
Maia Anderson –
Monday, August 17th, 2020
More articles on pharmacy: Women experience negative reactions 2x more than men due to clinical screening gender predisposition, research study findsUS, McKesson sign distribution offer for COVID-19 vaccineSanofi inks $3.68 B deal to purchase California autoimmune drugmaker.
© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this material? View our policies by clicking here.
The market research company launched its “Pharma, Biotech & & Medtech Half-Year Review 2020” which evaluated how the COVID-19 pandemic has actually affected the drug industry, scientific trials, FDA drug approvals and more..
Immunomedics breast cancer drug Trodelvy topped EvaluatePharmas list of the five greatest drug approvals in the first half of 2020..
Trodelvy (Immunomedics) treats breast cancer — $2.3 billion.